Li J H, Wu D, Yin Z D, Li Y X
Department of National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Feb 6;53(2):159-163. doi: 10.3760/cma.j.issn.0253-9624.2019.02.007.
To analyze the characteristics of epidemiology and () serogroups distribution for meningococcal meningitis (MM) cases in China from 2015 to 2017. The data of MM cases were collected from National Notifiable Diseases Registry System (NNDRS) and case-based MM surveillance system (MMSS) from 2015 to 2017; Demographic data are from the National Bureau of statistics. Inclusion criteria: the date of onset was January 1, 2015 to December 31, 2017, the status of infectious disease report card was "final examination card", the cases are classified as "laboratory confirmed cases" and "clinical diagnostic cases", and the card data information of disease name was "Meningococcal meningitis". According to the Diagnostic Criteria for Meningococcal meningitis (WS295-2008), laboratory confirm was made for reported cases or clinically diagnosed cases of meningococcal meningitis. From 2015 to 2017, a total of 325 MM cases were reported in China, with an average annual incidence of 0.007 9 per 100 000 population. And 148 cases were laboratory confirmed. There were 3, 15, 12, 5, 2 and 18 provinces which were reported serogroup A, B, C, W, Y, Others and NG MM Cases, respectively. Except for Tibet and Hainan, other provinces have reported group A cases; The provinces reporting group B, C, W and Y cases increased by 9, 11, 13 and 2 provinces in 2007, respectively compared with 2005. Serogroup B was the primary reason causing the cases of <1 year old and 1-6 years old children; and in this age group, 51.43% (18 cases) and 68.18% (15 cases) of group B were accounted for in laboratory confirmed, respectively; Serogroup C, others and NG was the major reason in the cases of 7-12 and >12 years old students and adults: 33.33% (5 cases) and 26.32% (20 cases) of group C were accounted for in laboratory confirmed respectively, then 26.67% (4 cases) and 34.21% (26 cases) of group others and NG were accounted for respectively; 2 cases of serogroup Y were all >12 years old. The epidemic serogroup of caused MM cases showed a diversifying trend. To develop and provide new vaccines for serogroup B and other bacteria groups should be one of the important tasks for MM control and prevention in the future.
分析2015 - 2017年中国流行性脑脊髓膜炎（MM）病例的流行病学特征及血清群分布情况。MM病例数据来自2015 - 2017年国家法定传染病报告系统（NNDRS）和基于病例的MM监测系统（MMSS）；人口统计学数据来自国家统计局。纳入标准：发病日期为2015年1月1日至2017年12月31日，传染病报告卡状态为“终审卡”，病例分类为“实验室确诊病例”和“临床诊断病例”，疾病名称的卡片数据信息为“流行性脑脊髓膜炎”。根据《流行性脑脊髓膜炎诊断标准》（WS295 - 2008），对报告的流行性脑脊髓膜炎病例或临床诊断病例进行实验室确诊。2015 - 2017年，中国共报告325例MM病例，年均发病率为十万分之0.0079。其中148例为实验室确诊病例。报告血清群A、B、C、W、Y、其他群和未分群MM病例的省份分别有3个、15个、12个、5个、2个和18个。除西藏和海南外，其他省份均有报告A群病例；与2005年相比，2007年报告B群、C群、W群和Y群病例的省份分别增加了9个、11个、13个和2个。B群是导致1岁及以下和1 - 6岁儿童发病的主要原因；在该年龄组中，实验室确诊病例中B群分别占51.43%（18例）和68.18%（15例）；C群、其他群和未分群是7 - 12岁学生及成人发病的主要原因：实验室确诊病例中C群分别占33.33%（5例）和26.32%（20例），其他群和未分群分别占26.67%（4例）和34.21%（26例）；Y群的2例病例均为12岁以上。导致MM病例的流行血清群呈多样化趋势。研发并提供针对B群及其他菌群的新型疫苗应是未来MM防控的重要任务之一。
